Cue Biopharma (CUE) Total Liabilities (2017 - 2025)

Cue Biopharma has disclosed Total Liabilities across 9 years of filings, most recently posting $15.8 million for Q4 2025.

• Total Liabilities for Q4 2025 came in at $15.8 million, up 7.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.8 million (up 7.41% YoY), and the FY2025 annual result was $15.8 million, up 7.41% from the prior year.
• Total Liabilities came in at $15.8 million for Q4 2025 at Cue Biopharma, down from $18.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $27.2 million in Q2 2023 to a low of $14.7 million in Q4 2024.
• The 5-year median for Total Liabilities is $21.6 million (2024), against an average of $21.3 million.
• Across the five-year window, Total Liabilities surged 120.91% in 2021 and tumbled 39.9% in 2024, its largest moves.
• Cue Biopharma's Total Liabilities stood at $17.9 million in 2021, then surged by 42.95% to $25.6 million in 2022, then slipped by 4.52% to $24.4 million in 2023, then sank by 39.9% to $14.7 million in 2024, then increased by 7.41% to $15.8 million in 2025.
• The last three Total Liabilities figures came in at $15.8 million (Q4 2025), $18.4 million (Q3 2025), and $22.5 million (Q2 2025), per Business Quant data.